Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: J Immunol. 2017 Sep 6;199(8):2631–2638. doi: 10.4049/jimmunol.1700615

Figure 4.

Figure 4

Synergy between human MAIT cell agonists and TLR agonists. A) Bioactive IL-12p70 in the supernatant of DC pulsed with E. coli supernatant in the presence or absence of allogeneic MAIT cells and blocking anti-CD40L or anti-MR1 antibodies. B) Bioactive IL-12p70 in the supernatant of DC pulsed with the indicated concentrations (ng/ml) of 5-A-RU/MG, LPS or R848 (μg/ml) in the presence or absence of allogeneic MAIT cells and blocking anti-CD40L or anti-MR1 antibodies. C) IFN-γ levels in the supernatant of MAIT-allogeneic DC co-cultures pulsed with E. coli supernatant in the presence or absence of blocking anti-CD40L, anti IL-12 or anti-MR1 antibodies. D) IFN-γ levels in the supernatant of MAIT-allogeneic DC co-cultures pulsed with the indicated concentrations (ng/ml) of 5-A-RU MG, LPS or R848 (μg/ml) in the presence or absence of blocking anti-CD40L or anti-MR1 antibodies. Data are from one experiment representative of four, values represent mean +/- SD. Two more donors are shown in Supplemental Fig. 2.